Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CSA Medical has developed a proprietary spray cryotherapy technology using liquid nitrogen to treat diseased tissue inside the body. Its lead product, the RejuvenAir System, targets damaged airway cells and overproduction of mucus in patients with COPD and chronic bronchitis. The system has completed pivotal trials in the U.S., received approval in Europe, and awaits FDA premarket approval. Clinical data suggest it enables rapid regrowth of healthy lung tissue without scarring by flash-freezing damaged cells.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CSA Medical.